Skip to main content

Advertisement

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study

Fig. 1

a, b Serum infliximab level and disease activity at week 54 in three stratified classes. Differences among three classes stratified on the basis of rheumatoid factor and anti-cyclic citrullinated peptide antibodies at week 0 in serum infliximab (IFX) level at week 54 (a) and with disease activity at week 54 b were evaluated by Kruskal-Wallis test. Disease activity was evaluated using Disease Activity Score in 28 joints based on C-reactive protein with the following REM cutoff levels: < 2.3, LDA ≥ 2.3 but < 2.7, MDA ≥ 2.7 but ≤ 4.1, and HDA > 4.1 [22]. HDA High disease activity, LDA Low disease activity without clinical remission, MDA Moderate disease activity, REM Clinical remission

Back to article page